Delta-slope of alpha-fetoprotein improves the ability to select liver transplant patients with hepatocellular cancer

HPB

Volumn 17, Issue 12, 2015, Pages 1085-1095

  Lai, Quirino ^a,b   Inostroza, Milton ^c   Rico Juri, Juan M ^d   Goffette, Pierre ^a   Lerut, Jan ^a  

^a CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^b POLICLINICO UMBERTO I   (Italy)

^c UNIVERSITY OF CONCEPCIÓN   (Chile)

^d CENTRO MÉDICO IMBANACO   (Colombia)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; AFP PROTEIN, HUMAN;

ADULT; AREA UNDER THE CURVE; ARTICLE; CANCER RECURRENCE; CANCER SURVIVAL; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE FREE INTERVAL; FEMALE; FOLLOW UP; HUMAN; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MORTALITY; PREDICTION; PROTEIN DETERMINATION; PROTEIN FUNCTION; RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY; SURVIVAL RATE; SURVIVAL TIME; ADVERSE EFFECTS; AGED; BLOOD; CARCINOMA, HEPATOCELLULAR; CHI SQUARE DISTRIBUTION; DECISION SUPPORT SYSTEM; DISEASE COURSE; DISEASE FREE SURVIVAL; FACTUAL DATABASE; INTENTION TO TREAT ANALYSIS; KAPLAN MEIER METHOD; LIVER NEOPLASMS; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; PATHOLOGY; PATIENT SELECTION; PREDICTIVE VALUE; PROPORTIONAL HAZARDS MODEL; RISK ASSESSMENT; RISK FACTOR; TIME FACTOR; TREATMENT OUTCOME; TUMOR RECURRENCE;

ADULT; AGED; ALPHA-FETOPROTEINS; AREA UNDER CURVE; CARCINOMA, HEPATOCELLULAR; CHI-SQUARE DISTRIBUTION; DATABASES, FACTUAL; DECISION SUPPORT TECHNIQUES; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INTENTION TO TREAT ANALYSIS; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; ODDS RATIO; PATIENT SELECTION; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; ROC CURVE; TIME FACTORS; TREATMENT OUTCOME;

EID: 84947032675     PISSN: 1365182X     EISSN: 14772574     Source Type: Journal    
DOI: 10.1111/hpb.12486     Document Type: Article

References (25)

1. Duvoux C, Roudot-Thoraval F, Decaens T, Pessione F, Badran H, Piardi T, et al,. (2012) Liver transplantation for hepatocellular carcinoma: a model including α-fetoprotein improves the performance of Milan criteria. Gastroenterology 143: 986-994.
2. Vibert E, Azoulay D, Hoti E, Iacopinelli S, Samuel D, Salloum C, et al,. (2010) Progression of alphafetoprotein before liver transplantation for hepatocellular carcinoma in cirrhotic patients: a critical factor. Am J Transplant 10: 129-137.
3. Lai Q, Lerut J,; European Hepatocellular Cancer Liver Transplant Study Group. (2014) α-Fetoprotein and hepatocellular cancer recurrence: a paradigm of the chaos theory. Liver Transpl 20: 1283.
4. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, et al,. (2001) Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 35: 421-430.
5. Bruix J, Sherman M,; Practice Guidelines Committee, American Association for the Study of Liver Diseases. (2005) Management of hepatocellular carcinoma. Hepatology 42: 1208-1236.
6. Sotiropoulos GC, Paul A, Molmenti E, Lang H, Frilling A, Napieralski BP, et al,. (2005) Liver transplantation for hepatocellular carcinoma in cirrhosis within the Eurotransplant area: an additional option with "livers that nobody wants". Transplantation 80: 897-902.
7. European Association for the Study of the Liver; European Organisation for Research and Treatment of Cancer. (2012) EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 56: 908-943.
8. Lencioni R, Llovet JM,. (2010) Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 30: 52-60.
9. Merani S, Majno P, Kneteman NM, Berney T, Morel P, Mentha G, et al,. (2011) The impact of waiting list alpha-fetoprotein changes on the outcome of liver transplant for hepatocellular carcinoma. J Hepatol 55: 814-819.
10. Toso C, Dupuis-Lozeron E, Majno P, Berney T, Kneteman NM, Perneger T, et al,. (2012) A model for dropout assessment of candidates with or without hepatocellular carcinoma on a common liver transplant waiting list. Hepatology 56: 149-156.
11. Ciccarelli O, Lai Q, Goffette P, Finet P, De Reyck C, Roggen F, et al,. (2012) Liver transplantation for hepatocellular cancer: UCL experience in 137 adult cirrhotic patients. Alpha-foetoprotein level and locoregional treatment as refined selection criteria. Transpl Int 25: 867-875.
12. Lai Q, Avolio AW, Lerut J, Singh G, Chan SC, Berloco PB, et al,. (2012) Recurrence of hepatocellular cancer after liver transplantation: the role of primary resection and salvage transplantation in East and West. J Hepatol 57: 974-979.
13. Mazzaferro V, Bhoori S, Sposito C, Bongini M, Langer M, Miceli R, et al,. (2011) Milan criteria in liver transplantation for hepatocellular carcinoma: an evidence-based analysis of 15 years of experience. Liver Transpl 17 (Suppl. 2): S44-57.
14. Toso C, Kneteman NM, James Shapiro AM, Bigam DL,. (2009) The estimated number of patients with hepatocellular carcinoma selected for liver transplantation using expanded selection criteria. Transpl Int 22: 869-875.
15. Lai Q, Lerut JP,. (2014) Hepatocellular cancer: how to expand safely inclusion criteria for liver transplantation. Curr Opin Organ Transplant 19: 229-234.
16. Mehta N, Yao FY,. (2013) Moving past "One size (and number) fits all" in the selection of candidates with hepatocellular carcinoma for liver transplantation. Liver Transpl 19: 1055-1058.
17. Mazzaferro V, Llovet JM, Miceli R, Bhoori S, Schiavo M, Mariani L, et al,. (2009) Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol 10: 35-43.
18. Lai Q, Melandro F, Pinheiro RS, Donfrancesco A, Fadel BA, Levi Sandri GB, et al,. (2012) Alpha-fetoprotein and novel tumor biomarkers as predictors of hepatocellular carcinoma recurrence after surgery: a brilliant star raises again. Int J Hepatol 2012: 893103.
19. Mehta N, Dodge JL, Goel A, Roberts JP, Hirose R, Yao FY,. (2013) Identification of liver transplant candidates with hepatocellular carcinoma and a very low dropout risk: implications for the current organ allocation policy. Liver Transpl 19: 1343-1353.
20. Cucchetti A, Piscaglia F, Grigioni AD, Ravaioli M, Cescon M, Zanello M, et al,. (2010) Preoperative prediction of hepatocellular carcinoma tumour grade and micro-vascular invasion by means of artificial neural network: a pilot study. J Hepatol 52: 880-888.
21. Zheng SS, Xu X, Wu J, Chen J, Wang WL, Zhang M, et al,. (2008) Liver transplantation for hepatocellular carcinoma: Hangzhou experiences. Transplantation 85: 1726-1732.
22. Takada Y, Uemoto S,. (2010) Liver transplantation for hepatocellular carcinoma: the Kyoto experience. J Hepatobiliary Pancreat Sci 17: 527-532.
23. Hameed B, Mehta N, Sapisochin G, Roberts JP, Yao FY,. (2014) Alpha-fetoprotein level > 1000 ng/mL as an exclusion criterion for liver transplantation in patients with hepatocellular carcinoma meeting the Milan criteria. Liver Transpl 20: 945-951.
24. Lai Q, Avolio AW, Graziadei I, Otto G, Rossi M, Tisone G, et al,. (2013) Alpha-fetoprotein and modified response evaluation criteria in solid tumors progression after locoregional therapy as predictors of hepatocellular cancer recurrence and death after transplantation. Liver Transpl 19: 1108-1118.
25. Yao FY, Hameed B, Mehta N, Roberts JP,. (2014) Response to letter to the editors. Liver Transpl 20: 1285.